CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer with limited treatment options.
• Chimeric antigen receptor (CAR) T cell therapy has shown success in B cell leukemias but is less established for T-ALL.
• CD147 is identified as a highly expressed antigen on T-ALL tumor cells.

Purpose of the Study:

• To investigate the potential of CD147 as a target for CAR T cell therapy in T-ALL.
• To construct and evaluate the efficacy and safety of CD147-CAR T cells for T-ALL treatment.

Main Methods:

• Construction of CD147-specific CAR T cells using a humanized single-chain variable fragment.
• Assessment of CAR T cell proliferation, memory cell preservation, and cytokine release.
• Evaluation of anti-tumor activity against T-ALL cell lines and primary blasts in vitro.
• Testing efficacy and safety in a T-ALL xenograft mouse model.

Main Results:

• CD147-CAR T cells demonstrated effective proliferation and preserved memory T cell subsets.
• Potent anti-tumor activity was observed against T-ALL cells, with significant cytokine production.
• CD147-CAR T cells showed safety towards normal cells and CD147-deficient cells.
• In vivo studies showed robust protection against T-ALL progression and improved survival in mice.

Conclusions:

• CD147 is a viable and promising target antigen for CAR T cell therapy in T-ALL.
• CD147-CAR T cells offer a potential new therapeutic strategy for T-ALL with a favorable safety profile.
• Further clinical investigation of CD147-CAR T cells for T-ALL is warranted.